ZellScanner ONE

项目摘要/摘要 这项申请是为购买Canopy Biosciences ZellScanner One高复用芯片而提出的 细胞仪。匹兹堡大学没有ZellScanner成像平台 迈尔斯。作为一种独特的仪器，ZellScanner系统结合了 多参数流式细胞术(标记共表达，定量，灵敏)与 显微镜(位置信息、组织结构、亚细胞细节)以进行分析 高度定义的免疫亚群及其在天然组织中的空间定位 微环境。如此高含量的成像允许对免疫细胞的深入了解 组织定位背景下的亚群。该仪器将放置在 匹兹堡大学学院的统一流式细胞术核心，这是一个集中的核心 医学部。统一流量核心目前为180多个PI和500个个人用户提供服务。对于 建议的工具，主要用户包括13个公共投资机构(10个国家卫生研究院资助)，另有5个公共投资机构为次要用户。 这些PIS总共有超过2000万美元的NIH资助的直接成本，其中至少有4 不同的学院。一个主要的研究焦点是免疫学和联合免疫的广泛领域。 疾病，与姐妹学科，如移植，风湿学，血管生物学， 肿瘤学也得到了很好的代表。而统一的流式细胞仪核心则配备了 传统的(虽然繁忙)分析仪和分选器，ZellScanner芯片细胞仪带来了 我们的研究能力有了全新的广度。我们的初步和演示工作证明 对我们来说，这一仪器将真正使我们的调查人员在他们的 研究。这件乐器的演示阶段确实在PI和 亲身实践的用户。这台新机器将得到统一流式细胞仪工作人员的精心保养 CORE拥有广泛的基础设施和文化来培训用户，负责监督 并确保它是自给自足的。两名经验丰富的核心人员将负责 在ZellScanner单元上进行的实验的概念和日常方面。我们将开始并 每天早上对机器进行认证并排除任何问题，就像我们在 工作时间。因此，它将对企业的生产力产生显著影响 优秀且资金充足的小灵通调查人员队伍。

Project Summary/Abstract This request is for funds to purchase a Canopy Biosciences ZellScanner One high-multiplexing chip cytometer. There is no ZellScanner imaging platform at the University of Pittsburgh or within 100 miles. Unique as an instrument, the ZellScanner system combines the strengths of multiparameter flow cytometry (marker co-expression, quantitative, sensitive) with microscopy (positional information, tissue architecture, subcellular detail) to permit analysis of highly defined immune subsets and their spatial positioning in the native tissue microenvironment. Such high content imaging allows for deep insights into immune cell subpopulations in the context of tissue localization. The instrument will be housed within the Unified Flow Cytometry Core, a centralized core, at the University of Pittsburgh School of Medicine. The Unified Flow Core currently serves over 180 Pis and 500 individual Users. For the proposed instrument, Major Users include 13 Pis (10 NiH funded) with another 5 Pis as Minor Users. Together, these Pis have over $20 M in NiH-funded direct costs from at least 4 different institutes. A major research focus is in the broad area of immunology and allied immune diseases, with sister disciplines such as transplantation, rheumatology, vascular biology, and oncology also well represented. While the Unified Flow Cytometry Core is well-endowed with traditional (though busy) analyzers and sorters, the ZellScanner chip cytometer brings totally new breadth to our research capabilities. Our preliminary and demo work proved to us that this instrument will truly allow our investigators to break new ground in their research. The demo phase of this instrument indeed created great excitement among the Pis and hands-on Users. The new machine will be well cared for by the staff of the Unified Flow Cytometry Core, which has an extensive infrastructure and culture in place to train Users, oversee the machine and ensure that it is self-supporting. Two experienced core personnel will be responsible for the conceptual and day to day aspects of experiments on the ZellScanner unit. We will start and certify the machine each morning and troubleshoot any problems, as we will do at any time during working hours. As such, it will have a remarkable impact on the productivity of an outstanding and well-funded cohort of PHS investigators.